Ardsley Advisory Partners’s Standard BioTools LAB Stock Holding History

Ardsley Advisory Partners’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30,000	Closed	-$223K	–	167
2020 Q3	$223K	Sell	30,000 -10,000	-25%	-$69K	0.04%	123
2020 Q2	$160K	Buy	+40,000	New	+$139K	0.03%	118
2014 Q3	–	Sell	-7,500	Closed	-$221K	–	229
2014 Q2	$221K	Buy	+7,500	New	+$240K	0.03%	221

Other funds holding LAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Ardsley Advisory Partners's LAB Position: Q4 2020 in Review

Ardsley Advisory Partners sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 30,000 shares — an estimated $223K sold.

Ardsley Advisory Partners first reported a position in LAB in Q2 2014 and held it in 3 quarters. The position peaked at $223K in Q3 2020. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

Ardsley Advisory Partners reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 30,000 Standard BioTools shares in Q4 2020, an estimated $223K.
Ardsley Advisory Partners first reported a position in Standard BioTools in Q2 2014 and held it in 3 quarters.
Ardsley Advisory Partners's Standard BioTools position peaked at $223K in Q3 2020.
145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Ardsley Advisory Partners's 13F filing for Q4 2020, filed 16 Feb 2021.